Skip to content

Products to prevent both pregnancy and HIV begin to emerge

Dr Alexandra Minnis presenting to HIVR4P 2021.

Once-a-month PrEP pill easily passes its first big test

Professor Sharon Hillier at HIVR4P

A triumph for injectable PrEP, but a sobering result for oral PrEP

Professor Sinead Delany-Moretlwe presenting HPTN 084's study design

Antibody-based PrEP did not stop most types of HIV – but is still hailed as a ‘game changer’

Professor Larry Corey, principal researcher of the AMP studies, speaking at HIVR4P

Anthony Fauci: “I don’t do this because I’m a hero. I do it because it’s necessary.”

Anthony Fauci (top left) with Michell Warren and Catherine Hankins

Study of injectable PrEP reports the best efficacy seen yet for any form of PrEP in women

Image: GCIS/Government ZA. Creative Commons licence. Image is for illustrative purposes only.

Similar benefits and barriers to injectables for HIV prevention and treatment reported by US women

CDC/Unsplash

Injectable PrEP offers superior efficacy to oral PrEP in clinical trial

Image: Raphael Landovitz (bottom left) at an AIDS 2020 online press conference.

Injectable antiretrovirals for HIV treatment or prevention: ambivalent views of potential users

funnyangel/Shutterstock.com